Literature DB >> 35551656

Melanoma: An immunotherapy journey from bench to bedside.

Vishal Navani1, Moira C Graves2, Hiren Mandaliya3, Martin Hong3, Andre van der Westhuizen2,3, Jennifer Martin2,4, Nikola A Bowden2.   

Abstract

Melanoma gave science a window into the role immune evasion plays in the development of malignancy. The entire spectrum of immune focused anti-cancer therapies has been subjected to clinical trials in this disease, with limited success until the immune checkpoint blockade era. That revolution launched first in melanoma, heralded a landscape change throughout cancer that continues to reverberate today.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  CTLA-4; Immune checkpoint; Immunotherapy; Immunotherapy resistance; Immunotherapy response; Melanoma; PD-1; PD-L1

Mesh：

Substances：

Year:  2022        PMID： 35551656     DOI： 10.1007/978-3-030-96376-7_2

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


  141 in total

1.  Spontaneous regression of melanoma may offer insight into cancer immunology.

Authors:  C Printz
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

Review 2.  Autocrine and paracrine regulation by cytokines and growth factors in melanoma.

Authors:  E Lázár-Molnár; H Hegyesi; S Tóth; A Falus
Journal:  Cytokine       Date:  2000-06       Impact factor: 3.861

3.  M-1/M-2 macrophages and the Th1/Th2 paradigm.

Authors:  C D Mills; K Kincaid; J M Alt; M J Heilman; A M Hill
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

Review 4.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

Review 5.  Myeloid-Derived Suppressor Cells.

Authors:  Dmitry I Gabrilovich
Journal:  Cancer Immunol Res       Date:  2017-01       Impact factor: 11.151

6.  Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate.

Authors:  Masao Furuhashi; Tobias Sjöblom; Alexandra Abramsson; Jens Ellingsen; Patrick Micke; Hong Li; Erika Bergsten-Folestad; Ulf Eriksson; Rainer Heuchel; Christer Betsholtz; Carl-Henrik Heldin; Arne Ostman
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

Review 7.  How regulatory T cells work.

Authors:  Dario A A Vignali; Lauren W Collison; Creg J Workman
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

8.  Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.

Authors:  Dale Han; Jonathan S Zager; Yu Shyr; Heidi Chen; Lynne D Berry; Sanjana Iyengar; Mia Djulbegovic; Jaimie L Weber; Suroosh S Marzban; Vernon K Sondak; Jane L Messina; John T Vetto; Richard L White; Barbara Pockaj; Nicola Mozzillo; Kim James Charney; Eli Avisar; Robert Krouse; Mohammed Kashani-Sabet; Stanley P Leong
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

9.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.

Authors:  C G Clemente; M C Mihm; R Bufalino; S Zurrida; P Collini; N Cascinelli
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

10.  Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma.

Authors:  Wendy K Nevala; Celine M Vachon; Alexey A Leontovich; Christopher G Scott; Michael A Thompson; Svetomir N Markovic
Journal:  Clin Cancer Res       Date:  2009-02-24       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.